[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100660442":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":20,"studyPopulation":13,"armGroups":21,"interventions":36,"overallOfficials":13,"centralContacts":42,"locations":48,"responsibleParty":71,"collaborators":13,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":13,"eligibilityCriteria":79,"healthyVolunteers":75,"sex":80,"minAge":81,"maxAge":13,"enrollmentInfo":82,"targetDuration":13,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":13,"overallStatus":51,"whyStopped":13,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"LTZ Therapeutics, Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Characterize the Safety and Tolerability of LTZ-232 in metastatic colorectal cancer and other solid tumors using the incidence, severity, and type of adverse events according to CTCAE v5.0.","To determine the incidence, severity, and type of adverse events according to NCI and CTCAE v5.0 and assessment of protocol defined dose limiting toxicity criteria.","Up to 24 months",null,{"allocation":15,"interventionModel":16,"interventionModelDescription":13,"primaryPurpose":17,"observationalModel":13,"timePerspective":13,"maskingInfo":18},"NON_RANDOMIZED","SEQUENTIAL","TREATMENT",{"masking":19,"maskingDescription":13,"whoMasked":13},"NONE","LTZ-232 is an engineered anti-EPCAM bispecific antibody designed to activate tumor-associated macrophages to phagocytose and kill tumor cells.",[22,28,32],{"label":23,"type":24,"description":25,"interventionNames":26},"Dose Escalation in metastatic colorectal cancer","EXPERIMENTAL","Participants in this arm will participate in one (1) of up to eight (8) escalating defined dose level cohorts. Participants may receive LTZ-232 intravenously up to 24 months unless treatment discontinuation criteria are met.",[27],"Drug: LTZ-232",{"label":29,"type":24,"description":30,"interventionNames":31},"Safety\u002FPK\u002FPharmacodynamic Cohorts","Participants may be dosed with LTZ-232 intravenously at levels previously declared safe to further explore safety and clinical activity at particular dose levels.",[27],{"label":33,"type":24,"description":34,"interventionNames":35},"Dose Expansion in metastatic colorectal cancer and other solid tumor types","Participants with unresectable or metastatic colorectal cancer and other specific solid tumor types at a LTZ-232 dosing regimen(s) identified from dose escalation.",[27],[37],{"type":38,"name":39,"description":40,"armGroupLabels":41,"otherNames":13},"DRUG","LTZ-232","LTZ-232 will be administered intravenously every two weeks for up to 24 months unless treatment discontinuation criteria are met.",[23,33,29],[43],{"name":44,"role":45,"phone":46,"phoneExt":13,"email":47},"Sherry Unabia","CONTACT","669-207-0084","sherry.unabia@ltztherapeutics.com",[49],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"HonorHealth Research Institute","RECRUITING","Scottsdale","Arizona","85258","United States","US",{"type":58,"coordinates":59},"Point",[60,61],-111.89903,33.50921,{"lat":61,"lon":60},[64,68],{"name":65,"role":45,"phone":66,"phoneExt":13,"email":67},"Stephanie Stanford","480-323-1350","stsanford@honorhealth.com",{"name":69,"role":70,"phone":13,"phoneExt":13,"email":13},"Sunil Sharma, MD","PRINCIPAL_INVESTIGATOR",{"type":72,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR","100660442","phase-1-this-is-a-phase-11b-study-to-evaluate-the-safety-and-preliminary-antitumor-activity-of-ltz-232-in-participants-with-advancedmetastatic-colorectal-cancer-and-other-solid-tumors-100660442",false,"NCT07878988","This is a Phase 1\u002F1b Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced\u002FMetastatic Colorectal Cancer and Other Solid Tumors","A Phase 1\u002F1b, Muticenter Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced\u002FMetastatic Colorectal Cancer and Other Solid Tumors","Inclusion Criteria:\n\n* Advanced \u002Fmetastatic colorectal tumors that have failed standard treatments\n* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)\n* Eastern Cooperative Oncology Group performance status (ECOG PS) ≤ 1\n* Adequate organ function based on laboratory testing\n\nExclusion Criteria:\n\n* Active infection with hepatitis B or C\n* Uncontrolled CNS metastases\n* Active autoimmune disease\n* Clinically significant cardiovascular disease not adequately controlled with medication or impaired function\n* Previous treatment with EpCAM targeting agent\n* Pregnant or breast feeding\n* Non-colorectal active malignancy within 3 years that could interfere with study interpretation","ALL","18 Years",{"count":83,"type":84},152,"ESTIMATED","INTERVENTIONAL",[87],"PHASE1","This is a first-in-human, Phase 1, multi-center, open-label study to characterize the safety, pharmacokinetics, pharmacodynamics, and preliminary anti tumor activity of LTZ-232 as monotherapy in adult participants with unresectable or metastatic colorectal cancer and other solid tumors failing standard therapies.",[90,91,92,93,94],"Colorectal Cancer","Advanced\u002FMetastatic Solid Tumor","Solid Tumor (Phase I)","EPCAM","Colon Cancer","2026-10-30",{"date":97,"type":98},"2026-11-03","ACTUAL",{"date":100,"type":98},"2026-10-28",{"date":102,"type":84},"2031-12",{"name":5,"class":6},1]